Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome

Chest

Volumn 134, Issue 4, 2008, Pages 686-692

  Dorkova, Zuzana ^a   Petrasova, Darina ^b   Molcanyiova, Angela ^c   Popovnakova, Marcela ^c   Tkacova, Ruzena ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^b Central Laboratory of Clinical Cytometry   (Slovakia)

^c LABMED   (Slovakia)

Author keywords

Compliance; Continuous positive airway pressure; Insulin resistance; Metabolic syndrome; Risk factors; Sleep apnea

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; MALONALDEHYDE; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALGORITHM; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SLEEP APNEA SYNDROME;

EID: 54249085473     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0556     Document Type: Article

References (36)

1. Mooe T, Franklin KA, Holmstrom K, et al. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 2001; 164:1910-1913
2. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046-1053
3. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378-1384
4. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29:720-727
5. Vgontzas AN, Bixler EO, Chroussos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9:211-224
6. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-B-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174:824-830
7. Barcelo A, Barbe F, Llompart E, et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004; 117:118-121
8. Minoguchi K, Yokoe T, Tanaka A, et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006; 28:378-385
9. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172:613-618
10. Bazzano LA, Khan Z, Reynolds K, et al. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007; 50:417-423
11. Steiropoulos P, Tsara V, Nena E, et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007; 132:843-851
12. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169:156-162
13. Harsch IA, Schahin SP, Bruckner K, et al. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 2004; 71:252-259
14. Babu AR, Herdegen J, Fogelfeld L, et al. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005; 165:447-452
15. Lindberg E, Berne C, Elmasry A, et al. CPAP treatment of a population-based sample: what are the benefits and the treatment compliance? Sleep Med 2006; 7:553-560
16. Smurra M, Philip P, Taillard J, et al. CPAP treatment does not affect glucose-insulin metabolism in sleep apneic patients. Sleep Med 2001; 2:207-213
17. West SD, Nicoll DJ, Wallace TM, et al. The effect of CPAP on insulin resistance and hbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62:969-974
18. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective therapy. Proc Am Thorac Soc 2008; 5:173-178
19. Shiina K, Tomyiama H, Takata Y, et al. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. Hypertens Res 2006; 29:433-441
20. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels, Belgium: International Diabetes Federation, 2005
21. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring systems for sleep stages of human subjects. Los Angeles, CA: UCLA Brain Information Service/Brain Research Institute, 1968
22. Weaver TE, Kribbs NB, Pack AI, et al. Night-to-night variability in CPAP use over the first three months of treatment. Sleep 1997; 20:278-283
23. Oliver Z, Hoffstein V. Predicting effective continuous positive airway pressure. Chest 2000; 117:1061-1064
24. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15:212-216
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
26. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008; 117:743-753
27. Borgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006; 27:121-127
28. Robinson GV, Pepperell JC, Segal HC, et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomized controlled trials. Thorax 2004; 59:777-782
29. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107:1129-1134
30. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005; 26:2435-2439
31. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165:1217-1239
32. Radikova Z, Koska J, Huckova M, et al. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 2006; 114:249-256
33. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care 2007; 30:753-759
34. Harsch IA, Konturek PC, Koebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003; 22:251-257
35. Martinez-Garcia MA, Gomez-Aldaravi R, Soler-Cataluna JJ, et al. Positive effect of CPAP treatment on the control of difficult-to-treat hypertension. Eur Respir J 2007; 29:951-957
36. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27:1498-1495